Showing results (161-170 of 672) with videos related to
Sort By:
Pageof 68
Pharmacological Reviews|September 13, 2025
The evolution of lipid-lowering drugs in the management of cardiovascular disease risk: From the first cardiovascular disease risk-reducing therapies to the novel challenging strategiesDoriane Henry, Eric Baugé, Bart Staels, et al.Nature Metabolism|December 14, 2021
Peroxisomal β-oxidation acts as a sensor for intracellular fatty acids and regulates lipolysisLianggong Ding, Wenfei Sun, Miroslav Balaz, et al.Nature Cardiovascular Research|January 17, 2024
Timed use of digoxin prevents heart ischemia-reperfusion injury through a REV-ERBα-UPS signaling pathwayManjula Vinod, Alexandre Berthier, Xavier Maréchal, et al.The Journal of Clinical Investigation|May 12, 2015
MicroRNA-26a regulates insulin sensitivity and metabolism of glucose and lipidsXianghui Fu, Bingning Dong, Yan Tian, et al.Circulation Research|May 15, 2004
Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cellsNikolaus Marx, Hélène Duez, Jean-Charles Fruchart, et al.Journal of Cellular and Molecular Medicine|November 5, 2011
Cell-derived microparticles in atherosclerosis: biomarkers and targets for pharmacological modulation?Morgane Baron, Chantal M Boulanger, Bart Staels, et al.The Proceedings of the Nutrition Society|November 17, 2016
Intestinal bile acid receptors are key regulators of glucose homeostasisMohamed-Sami Trabelsi, Sophie Lestavel, Bart Staels, et al.Trends in Endocrinology and Metabolism: TEM|September 8, 2004
Genomic and non-genomic interactions of PPARalpha with xenobiotic-metabolizing enzymesOlivier Barbier, Coralie Fontaine, Jean-Charles Fruchart, et al.Endocrinology|March 8, 2008
Systemic and distal repercussions of liver-specific peroxisome proliferator-activated receptor-alpha control of the acute-phase responseRoxane M Mansouri, Eric Baugé, Bart Staels, et al.Expert Opinion on Emerging Drugs|August 31, 2006
Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosisBenoit Pourcet, Jean-Charles Fruchart, Bart Staels, et al.Pageof 68